1993—2023年国际儿童及青少年分化型甲状腺癌131I治疗文献计量分析

doi:10.19401/j.cnki.1007-3639.2024.12.007

摘要/Abstract

摘要：

本研究通过文献计量学方法，对国际儿童及青少年分化型甲状腺癌（differentiated thyroid cancer in children and adolescents，caDTC）放射性碘131（iodine 131，¹³¹I）治疗领域的研究现状与发展趋势进行分析。检索 Web of Science Core Collection（WoSCC）数据库，检索时间限定为1993年1月1日—2023年12月1日，使用VOSviewer 1.6.20与CiteSpace 6.2.R6进行可视化分析。共计150篇文献符合本研究纳入标准，首篇发表于1994年;近30年来，caDTC ¹³¹I治疗领域文献年发行量尽管自2020年以来略有下降，但整体上呈波动上升趋势;31个国家/地区涉足该领域，美国、意大利和中国的文献产出最多，全球合作网络分析显示欧美机构间合作相对更紧密;该领域期刊多为内分泌及代谢或儿科类别，Thyroid和Journal of Clinical Endocrinology & Metabolism具有重要影响力;2015年发表的《儿童甲状腺结节与分化型甲状腺癌诊治指南》（Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer）是总被引次数最多的文献;共计869名学者发表过该领域论文，高发文量学作者主要来自欧美地区，我国黄蕤学者上榜前十;聚类分析显示研究热点包括“metastasis（转移）”、“fusion oncogene（融合致癌基因）”、“late effects（迟发效应）”;关键词时序分析显示“¹³¹I”持续受关注时间最长，其他重要标签包括“management guidelines（管理指南）”、“ 2nd primary malignancy（第二原发恶性肿瘤）”及“term follow up（定期随访）”，涵盖caDTC ¹³¹I治疗的标准制定、疗效及不良事件监测等内容。当前在国际caDTC ¹³¹I治疗领域，欧美地区占据主导地位，中国可依托患者群体规模优势加强国内外合作，以提升我国在该领域的研究影响力。在当前¹³¹I治疗仍待规范的情况下，聚类结果提示应尽快统一临床实践中的caDTC用¹³¹I治疗标准。未来该领域研究需关注术后¹³¹I治疗的疗效与安全性监测，深入探索RET融合等基因特征与¹³¹I疗效间的关联，寻找¹³¹I难治性caDTC的预测标志物，以期为临床上作出¹³¹I治疗的决策提供有力支持。

关键词: 分化型甲状腺癌, 儿童及青少年, 放射性碘, 文献计量学, 数据可视化

Abstract:

This study aimed to delineate the characteristics and trends of scholarly publications within the domain of ¹³¹I-therapy for differentiated thyroid cancer in children and adolescents (caDTC) through a bibliometric approach. A retrieval of publications concerning ¹³¹I-therapy for caDTC from the Web of Science Core Collection (WoSCC) database was conducted, spanning from January 1993 to December 2023. Visualization analysis was performed utilizing VOSviewer 1.6.20 and CiteSpace 6.2.R6 software. A total of 150 English publications, including articles and reviews, were analyzed in this study, with the earliest work traced back to 1994. A fluctuating yet overall ascending trend in annual publication volume was observed over the three decades, with a slight recent downturn post 2020. The United States, Italy and China emerged as the most prolific contributors. International network mapping revealed robust collaboration predominantly between European and American entities. Journals featuring predominantly in this field were primarily categorized under endocrinology, metabolism or pediatrics, with Thyroid and Journal of Clinical Endocrinology & Metabolism recognized as highly influential. The "Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer", published in 2015, was the most frequently cited document. A total of 869 scholars published literature in this field, with high-producing scholars mainly coming from Europe and the United States. Huang Rui from China was ranked among the top ten. References and keywords clustering illuminated focal points of research such as “metastasis”, “fusion oncogene”, and “late effects”. The timelines viewer of keywords underscored enduring interest in “¹³¹I”, complimented by significant terms like “management guidelines”, “2nd primary malignancy”, and “term follow up”, encompassing standardization, efficacy, and surveillance of adverse events in ¹³¹I-therapy for caDTC. The ¹³¹I-therapy research for caDTC is largely steered by European and American efforts. China’s substantial patient demographic is positioned to enhance both domestic and international collaborative research. The current paucity of clinical standardization in ¹³¹I-therapy for caDTC needs to be addressed. Future endeavors should be scrutinizing the short and long-term efficacy of ¹³¹I-therapy of caDTC, probing into the relationship between molecular profiles such as RET fusion and the therapeutic effectiveness of ¹³¹I-therapy, and pinpointiing efficacious biomarkers for ¹³¹I-resistance, which are pivotal for informed decision-making in the therapeutic application of ¹³¹I-therapy for caDTC.

Key words: Differentiated thyroid cancer, Children and adolescents, Radioiodine, Bibliometric analysis, Data visualization

潘逸缙, 石聪, 孙郁青, 孙迪, 赵翊含, 彰金, 林岩松. 1993—2023年国际儿童及青少年分化型甲状腺癌¹³¹I治疗文献计量分析[J]. 中国癌症杂志, 2024, 34(12): 1123-1133.

PAN Yijin, SHI Cong, SUN Yuqing, SUN Di, ZHAO Yihan, ZHANG Jin, LIN Yansong. Global trends of ¹³¹I-therapy for differentiated thyroid cancer in children and adolescents: a bibliometric analysis (1993-2003)[J]. China Oncology, 2024, 34(12): 1123-1133.

图/表 7

图1

表1

表2

表3

图2

图3

图4

参考文献 25

[1]	中国临床肿瘤学会核医学专家委员会, 中国临床肿瘤学会甲状腺癌专家委员会, 中国医疗保健国际交流促进会甲状腺疾病专业委员会, 等. 儿童及青少年分化型甲状腺癌核医学诊治中国专家共识(2022年版)[J]. 中国癌症杂志, 2022, 32(5): 451-468.
	Expert Committee of Nuclear Medicine, Chinese Society of Clinical Oncology, Expert Committee of Thyroid Cancer, Chinese Society of Clinical Oncology, et al. Expert consensus on management of differentiated thyroid carcinoma in children and adolescents (2022 edition)[J]. Chin Oncol, 2022, 32(5): 451-468.
[2]	KUHLEN M, WELLBROCK M, KUNSTREICH M, et al. Incidence and temporal patterns of differentiated thyroid carcinoma in children and adolescents in Germany: a pooled analysis based on data from the German malignant endocrine tumor registry and the German childhood cancer registry[J]. Thyroid, 2024, 34(12): 1540-1550.
[3]	ZHENG R S, CHEN R, HAN B F, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
[4]	DE SOUSA M S A, NUNES I N, CHRISTIANO Y P, et al. Genetic alterations landscape in paediatric thyroid tumours and/or differentiated thyroid cancer: systematic review[J]. Rev Endocr Metab Disord, 2024, 25(1): 35-51.
[5]	FRANCIS G L, WAGUESPACK S G, BAUER A J, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2015, 25(7): 716-759.
[6]	GUAN Q, WANG Y. Pathology features and clinical significances of thyroid carcinoma in children and adolescents[J]. Chin J Pract Surg, 2022, 42(6): 638-43.
[7]	BOUCAI L, ZAFEREO M, CABANILLAS M E. Thyroid cancer: a review[J]. JAMA, 2024, 331(5): 425-435.
[8]	LIU Y J, WANG J F, HU X P, et al. Radioiodine therapy in advanced differentiated thyroid cancer: resistance and overcoming strategy[J]. Drug Resist Updat, 2023, 68: 100939.
[9]	PETERMANN-ROCHA F, DIAZ-TORO F, VALERA-GRAN D, et al. Bibliometric analysis of research on sarcopenic obesity: a review of scientific literature[J]. Obes Rev, 2024, 25(9): e13784.
[10]	SUN Z C, WANG X Y, XIAO J H, et al. Knowledge mapping and emerging trends in neural stem cell transplantation research for spinal cord injury: a bibliometric analysis (2004-2023)[J]. Int J Surg, 2024, 110(12): 8215-8219.
[11]	CHEN C M, SONG M. Visualizing a field of research: a methodology of systematic scientometric reviews[J]. PLoS One, 2019, 14(10): e0223994.
[12]	LIU X J, YUAN J Y, FENG Y F, et al. Knowledge graph and development hotspots of biochar as an emerging aquatic antibiotic remediator: a scientometric exploration based on VOSviewer and CiteSpace[J]. J Environ Manage, 2024, 360: 121165.
[13]	BOYACK K W, SMITH C, KLAVANS R. A detailed open access model of the PubMed literature[J]. Sci Data, 2020, 7(1): 408.
[14]	JOCHAM A, JOPPICH I, HECKER W, et al. Thyroid carcinoma in childhood: management and follow up of 11 cases[J]. Eur J Pediatr, 1994, 153(1): 17-22.
[15]	MU Z Z, ZHANG X, SUN D, et al. Characterizing genetic alterations related to radioiodine avidity in metastatic thyroid cancer[J]. J Clin Endocrinol Metab, 2024, 109(5): 1231-1240.
[16]	MU Z Z, ZHANG Y Q, SUN D, et al. Effect of BRAFV600E and TERT promoter mutations on thyroglobulin response in patients with distant-metastatic differentiated thyroid cancer[J]. Endocr Pract, 2022, 28(3): 265-270.
[17]	LEBBINK C A, LINKS T P, CZARNIECKA A, et al. 2022 European Thyroid Association guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma[J]. Eur Thyroid J, 2022, 11(6): e220146.
[18]	孙迪, 孙郁青, 张鑫, 等. 局部晚期或转移性儿童及青少年分化型甲状腺癌的基因特征与临床特征及¹³¹I疗效的关系[J]. 中国癌症杂志, 2022, 32(5): 380-387.
	SUN D, SUN Y Q, ZHANG X, et al. The relationship between genetic characteristics and clinical characteristics and the efficacy of ¹³¹I therapy in children and adolescents with locally advanced or metastatic differentiated thyroid cancer[J]. Chin Oncol, 2022, 32(5): 380-387.
[19]	NIES M, VASSILOPOULOU-SELLIN R, BASSETT R L, et al. Distant metastases from childhood differentiated thyroid carcinoma: clinical course and mutational landscape[J]. J Clin Endocrinol Metab, 2021, 106(4): e1683-e1697.
[20]	潘逸缙, 鞠高达, 慕转转, 等. 转移性儿童及青少年分化型甲状腺癌基因与临床特征的关系[J]. 中华医学杂志, 2024, 104(20): 1837-1843.
	PAN Y J, JU G D, MU Z Z, et al. The relationship between differentially expressed thyroid cancer genes and clinical characteristics in metastatic children and adolescents[J]. Natl Med J Chin, 2024, 104(20): 1837-1843.
[21]	PAWELCZAK M, DAVID R, FRANKLIN B, et al. Outcomes of children and adolescents with well-differentiated thyroid carcinoma and pulmonary metastases following ¹³¹I treatment: a systematic review[J]. Thyroid, 2010, 20(10): 1095-1101.
[22]	KIM K J, KIM K J, CHOI J, et al. Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer[J]. J Natl Cancer Inst, 2023, 115(6): 695-702.
[23]	VASSILOPOULOU-SELLIN R, GOEPFERT H, RANEY B, et al. Differentiated thyroid cancer in children and adolescents: clinical outcome and mortality after long-term follow-up[J]. Head Neck, 1998, 20(6): 549-555.
[24]	PASQUAL E, SCHONFELD S, MORTON L M, et al. Association between radioactive iodine treatment for pediatric and young adulthood differentiated thyroid cancer and risk of second primary malignancies[J]. J Clin Oncol, 2022, 40(13): 1439-1449.
[25]	ZHAO X L, CHEN M J, QI X J, et al. Association of radioiodine for differentiated thyroid cancer and second breast cancer in female adolescent and young adult[J]. Front Endocrinol, 2022, 12: 805194.

Rank	Country/region	Publications	Percentage	Total citations	Average citations	Collaboration strength
1	United States (US)	64	42.67%	2 643	41.30	24
2	Italy	16	10.67%	1 028	64.25	14
3	China	15	10.00%	190	12.67	1
4	Germany	13	8.67%	1 101	84.69	28
5	Japan	11	7.33%	869	79.00	18
5	Netherlands	11	7.33%	313	28.45	11
7	Canada	7	4.67%	886	126.57	10
8	India	6	4.00%	83	13.83	0
8	Turkey	6	4.00%	18	3.00	0
10	Belarus	5	3.33%	313	62.60	12

Rank	Institution	Publications	Total citations	Country/region	Average citations	Collaboration strength
1	University of Pennsylvania	11	813	US	73.91	24
2	Memorial Sloan-Kettering Cancer Center	7	297	US	42.43	7
3	Sichuan University	6	41	China	6.83	0
3	University of Pisa	6	167	Italy	27.83	2
3	Yale University	6	1 036	US	172.67	18
6	Children's Hospital of Philadelphia	5	720	US	144.00	13
6	University of Groningen	5	136	Netherlands	27.20	12
6	University of Pittsburgh	5	44	US	8.80	12
6	MD Anderson Cancer Center	5	814	US	162.80	10
6	University of Toronto	5	792	Canada	158.40	15
6	University of Würzburg	5	240	Germany	48.00	6

Rank	Author	Publications	Totalcitations	Average citations	H-index (WoS)	Institution	Country	Collaboration strength
1	Bauer A J	7	753	107.57	22	Children's Hospital of Philadelphia	USA	25
2	Kazahaya K	6	47	7.83	17	Children's Hospital of Philadelphia	USA	4
3	Huang R	6	41	6.83	13	Sichuan University	China	23
4	Links T P	5	136	27.20	53	University Medical Center Groningen	Netherlands	50
5	Mostoufi-Moab S	5	45	9.00	22	Children's Hospital of Philadelphia	USA	19
6	Tuttle R M	5	152	30.40	77	Memorial Sloan-Kettering Cancer Center	USA	4
7	van Santen H M	5	135	27.00	26	Wilhelmina Children's Hospital	Netherlands	50
8	Waguespack S G	5	814	162.80	46	MD Anderson Cancer Center	USA	8

1993—2023年国际儿童及青少年分化型甲状腺癌¹³¹I治疗文献计量分析

Global trends of ¹³¹I-therapy for differentiated thyroid cancer in children and adolescents: a bibliometric analysis (1993-2003)

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 7

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	耿倩倩, 杨爱民. 碘难治性分化型甲状腺癌的治疗进展及展望[J]. 中国癌症杂志, 2025, 35(1): 30-39.
[2]	李汝平, 杨辉. 放射性碘难治性甲状腺癌的临床试验现状及未来展望[J]. 中国癌症杂志, 2025, 35(1): 40-48.
[3]	王任飞, 卢改霞. 核医学分子影像在放射性碘难治性分化型甲状腺癌评估中的独特价值与争议[J]. 中国癌症杂志, 2025, 35(1): 49-57.
[4]	林秋玉, 王宇鑫, 林承赫. 靶向治疗与免疫治疗在放射性碘难治性分化型甲状腺癌中的应用与前景[J]. 中国癌症杂志, 2025, 35(1): 58-67.
[5]	姜晓彤, 刘锦川, 张迎强, 王瞳, 郭宁, 孙郁青, 石聪, 颜兵, 林岩松. 诊断性¹³¹I全身显像在分化型甲状腺癌¹³¹I治疗决策中的作用[J]. 中国癌症杂志, 2025, 35(1): 77-84.
[6]	任恒宇, 郝爽, 陈嘉健, 杨犇龙, 曹阿勇, 柳光宇, 邵志敏, 吴炅. 国内外乳房重建研究的现状和重点：一项文献计量学研究[J]. 中国癌症杂志, 2023, 33(6): 581-588.
[7]	孙迪, 孙郁青, 张鑫, 黄丽莎, 林岩松. 局部晚期或转移性儿童及青少年分化型甲状腺癌的基因特征与临床特征及¹³¹I疗效的关系[J]. 中国癌症杂志, 2022, 32(5): 380-387.
[8]	邓姝婷, 冯源, 钱凯, 郭凯, 王卓颖. 基因突变特征与儿童及青少年分化型甲状腺癌远处转移相关性的meta分析[J]. 中国癌症杂志, 2022, 32(5): 388-396.
[9]	齐萌芳, 田甜, 黄蕤. 不同年龄儿童及青少年分化型甲状腺癌患者的临床病理学特征与¹³¹I治疗分析[J]. 中国癌症杂志, 2022, 32(5): 404-409.
[10]	郭文婷, 慕转转, 李征, 张迎强, 靳晓娜, 林岩松. 可疑甲状腺球蛋白增高性分化型甲状腺癌患者经¹³¹I治疗后的临床转归[J]. 中国癌症杂志, 2022, 32(5): 410-416.
[11]	中国临床肿瘤学会核医学专家委员会, 中国临床肿瘤学会甲状腺癌专家委员会, 中国医疗保健国际交流促进会甲状腺疾病专业委员会, 中国人口文化促进会甲状腺疾病防治专业委员会. 儿童及青少年分化型甲状腺癌核医学诊治中国专家共识（2022年版）[J]. 中国癌症杂志, 2022, 32(5): 451-468.
[12]	梅晓然, 冯方, 王辉, 韦智晓. 摄碘阳性的分化型甲状腺癌淋巴结转移灶¹³¹I疗效分析[J]. 中国癌症杂志, 2022, 32(11): 1091-1097.
[13]	李孟娟, 刘莹, 张艳丽, 刘萌垚, 薛亚男, 苏丽萍, 张秀杰, 史铁英, 方凤奇, 刘基巍, 夏云龙. 基于文献计量学的国内外肿瘤心脏病学研究现状与热点分析[J]. 中国癌症杂志, 2022, 32(10): 925-935.
[14]	杨　珂，郑　容，林岩松. 儿童青少年甲状腺癌诊治指南解读及其进展——核医学部分[J]. 中国癌症杂志, 2019, 29(6): 401-411.
[15]	张立阳，刘春浩，曹　越，刘洪沨，高维生，李小毅. 125例复发/持续性分化型甲状腺癌再次手术及其预后影响因素分析[J]. 中国癌症杂志, 2019, 29(6): 412-417.